Abstract PS5-07-27: INAVO123: Phase 3 study of first-line inavolisib / placebo + a cyclin-dependent kinase 4/6 inhibitor + letrozole in participants with PIK3CA -mutated, hormone receptor-positive, HER2-negative, endocrine-sensitive advanced breast cancer